stockrow
Friday 6 November 2026
Export GRDN’s income statement to Excel — free account
Guardian Pharmacy Services, Inc.
GRDN Healthcare Medical Care Facilities
Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024.
- Revenue
- −1.68%
- EPS
- +133.3%
- Free cash flow
- +88.9%
Quarter to September 2026, against a year earlier
39.72
2.37
−5.63%
Follow GRDN
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
38.84 | 39.88 | 44.31 | 38.09 |
+8 more quarters Free account |
P/S ratio |
1.77 | 1.81 | 1.64 | 1.30 | |
P/FCF ratio |
27.19 | 33.23 | 33.93 | 23.26 | |
P/Operating CF |
59.55 | 88.31 | 393.38 | 54.25 | |
P/B ratio |
9.23 | 10.29 | 10.26 | 8.61 | |
Price to Tangible BV |
14.60 | 16.44 | 17.64 | 15.68 | |
EV/Sales |
1.72 | 1.78 | 1.62 | 1.28 | |
EV/EBITDA |
21.27 | 23.90 | 23.49 | 19.47 | |
EV/Operating CF |
21.93 | 26.30 | 26.57 | 18.46 | |
EV/FCF |
26.34 | 32.59 | 33.56 | 22.92 | |
Quick Ratio |
1.27 | 1.26 | 1.10 | 1.04 | |
Current Ratio |
1.65 | 1.65 | 1.46 | 1.38 | |
Net Debt/EBITDA |
(3.86) | (3.40) | (2.74) | (1.80) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.30 | 3.66 | 3.83 | 3.95 | |
Operating CF/Net income |
2.32 | 1.37 | 0.46 | 1.65 | |
Capex/Depreciation |
0.00 | (0.84) | (0.79) | (0.74) | |
Interest Coverage |
141.60 | 134.05 | 114.77 | 188.72 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.21% | 16.89% | 17.42% | 13.77% | |
Intangible Assets out of Total Assets |
0.21 | 0.22 | 0.23 | 0.24 | |
Share Based Compensation of Revenue |
0.74% | 0.83% | 0.55% | 0.27% | |
Graham Net Nets |
0.03 | 0.03 | 0.02 | 0.01 | |
Graham Number |
0.00 | 9.80 | 8.38 | 7.88 | |
Earnings Yield |
2.57% | 2.51% | 2.26% | 2.63% | |
Free Cash Flow Yield |
3.68% | 3.01% | 2.95% | 4.30% | |
Revenue per Share |
0.00 | 5.55 | 5.32 | 6.37 | |
Operating CF per Share |
0.00 | 0.47 | 0.10 | 0.55 | |
Capex per Share |
— | (0.08) | (0.07) | (0.07) | |
Free Cash Flow per Share |
0.00 | 0.40 | 0.02 | 0.49 | |
Cash per Share |
0.00 | 1.42 | 1.02 | 1.05 | |
Shareholders Equity per Share |
0.00 | 4.07 | 3.67 | 3.49 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 4.07 | 3.67 | 3.49 | |
Free Cash Flow |
43.37 | 25.14 | 1.31 | 30.37 | |
Working Capital |
115.73 | 100.63 | 74.64 | 60.93 | |
Capital Expenditures |
— | (4.89) | (4.75) | (4.23) | |
Net Current Asset Value |
82.76 | 68.73 | 40.67 | 26.90 | |
EV/EBIT |
26.57 | 30.44 | 30.48 | 25.45 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
27.43 | 31.04 | 30.82 | 25.82 | |
| Other line items | |||||
Average Receivables |
106.93 | 98.95 | 104.56 | 99.38 | |
Average Payables |
123.99 | 106.60 | 105.11 | 109.31 | |
Average Inventory |
52.46 | 47.30 | 45.30 | 41.95 | |
Average Assets |
440.91 | 399.96 | 380.47 | 366.73 | |
Average Common Equity |
237.61 | 218.66 | 197.82 | 183.95 |
Columns are period end dates · fundamentals updated 5 Nov 2026